Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Goldenberg

Showing results (751-760 of 968) with videos related to

Pageof 97
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 1999
The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragmentsS O Leung, Z Qu, H J Hansen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphomaM E Juweid, E Stadtmauer, G Hajjar, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 23, 2011
Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclideEric Frampas, Catherine Maurel, Patricia Remaud-Le Saëc, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 19, 2009
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphomaRobert M Sharkey, Habibe Karacay, Christine R Johnson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 1997
Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibodyM Juweid, R M Sharkey, A Alavi, et al.
The Biochemical Journal|November 15, 1996
Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomasH J Hansen, G L Ong, H Diril, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 6, 2004
Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal originManuel J Koppe, Robert P Bleichrodt, Annemieke C Soede, et al.
International Journal of Cancer|July 29, 1997
Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinomaR M Sharkey, R D Blumenthal, T M Behr, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 20, 2005
Comparison of IgG and F(ab')2 fragments of bispecific anti-RCCxanti-DTIn-1 antibody for pretargeting purposesFrank G van Schaijk, Otto C Boerman, Annemieke C Soede, et al.
Blood|January 25, 2012
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomasPankaj Gupta, David M Goldenberg, Edmund A Rossi, et al.
Pageof 97

Showing results (751-760 of 968) with videos related to

Sort By:
Pageof 97
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 1999
The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragmentsS O Leung, Z Qu, H J Hansen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphomaM E Juweid, E Stadtmauer, G Hajjar, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 23, 2011
Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclideEric Frampas, Catherine Maurel, Patricia Remaud-Le Saëc, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 19, 2009
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphomaRobert M Sharkey, Habibe Karacay, Christine R Johnson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 1997
Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibodyM Juweid, R M Sharkey, A Alavi, et al.
The Biochemical Journal|November 15, 1996
Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomasH J Hansen, G L Ong, H Diril, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 6, 2004
Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal originManuel J Koppe, Robert P Bleichrodt, Annemieke C Soede, et al.
International Journal of Cancer|July 29, 1997
Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinomaR M Sharkey, R D Blumenthal, T M Behr, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 20, 2005
Comparison of IgG and F(ab')2 fragments of bispecific anti-RCCxanti-DTIn-1 antibody for pretargeting purposesFrank G van Schaijk, Otto C Boerman, Annemieke C Soede, et al.
Blood|January 25, 2012
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomasPankaj Gupta, David M Goldenberg, Edmund A Rossi, et al.
Pageof 97